HK1206339A1 - N-aryltriazole compounds as lpar antagonists - Google Patents

N-aryltriazole compounds as lpar antagonists Download PDF

Info

Publication number
HK1206339A1
HK1206339A1 HK15106924.1A HK15106924A HK1206339A1 HK 1206339 A1 HK1206339 A1 HK 1206339A1 HK 15106924 A HK15106924 A HK 15106924A HK 1206339 A1 HK1206339 A1 HK 1206339A1
Authority
HK
Hong Kong
Prior art keywords
phenyl
methyl
triazol
biphenyl
hydrogen
Prior art date
Application number
HK15106924.1A
Other languages
English (en)
Chinese (zh)
Inventor
斯蒂芬．迪姆斯．加布里埃爾
斯蒂芬．迪姆斯．加布里埃尔
馬修．邁克爾．漢密爾頓
马修．迈克尔．汉密尔顿
錢義民
钱义民
阿奇尤特哈拉.西杜瑞
Original Assignee
霍夫曼-拉罗奇有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48628669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1206339(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 霍夫曼-拉罗奇有限公司 filed Critical 霍夫曼-拉罗奇有限公司
Publication of HK1206339A1 publication Critical patent/HK1206339A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK15106924.1A 2012-06-20 2013-06-17 N-aryltriazole compounds as lpar antagonists HK1206339A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261661953P 2012-06-20 2012-06-20
US61/661,953 2012-06-20
PCT/EP2013/062463 WO2013189865A1 (en) 2012-06-20 2013-06-17 N-aryltriazole compounds as lpar antagonists

Publications (1)

Publication Number Publication Date
HK1206339A1 true HK1206339A1 (en) 2016-01-08

Family

ID=48628669

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15106924.1A HK1206339A1 (en) 2012-06-20 2013-06-17 N-aryltriazole compounds as lpar antagonists

Country Status (22)

Country Link
US (1) US20150133512A1 (OSRAM)
EP (1) EP2864301A1 (OSRAM)
JP (1) JP2015520203A (OSRAM)
KR (1) KR20150011389A (OSRAM)
CN (1) CN104395299A (OSRAM)
AU (1) AU2013279513A1 (OSRAM)
BR (1) BR112014030674A2 (OSRAM)
CA (1) CA2869564A1 (OSRAM)
CL (1) CL2014003241A1 (OSRAM)
CO (1) CO7131357A2 (OSRAM)
EA (1) EA201492281A1 (OSRAM)
HK (1) HK1206339A1 (OSRAM)
IL (1) IL236087A0 (OSRAM)
IN (1) IN2014DN09352A (OSRAM)
MA (1) MA37762B1 (OSRAM)
MX (1) MX2014014711A (OSRAM)
PE (1) PE20142305A1 (OSRAM)
PH (1) PH12014502363A1 (OSRAM)
SG (1) SG11201407228PA (OSRAM)
UA (1) UA110310C2 (OSRAM)
WO (1) WO2013189865A1 (OSRAM)
ZA (1) ZA201408167B (OSRAM)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2844982A1 (en) 2011-08-15 2013-02-21 Intermune, Inc. Lysophosphatidic acid receptor antagonists
US20140213538A1 (en) * 2013-01-15 2014-07-31 Intermune, Inc. Lysophosphatidic acid receptor antagonists
MX382748B (es) 2013-03-15 2025-03-13 Epigen Biosciences Inc Compuestos heterociclicos utiles para el tratamiento de una enfermedad.
UY36060A (es) 2014-04-02 2015-10-30 Bayer Pharma AG Compuestos de azol sustituidos con amida
US10023554B2 (en) 2014-06-27 2018-07-17 Ube Industries, Ltd. Halogen-substituted heterocyclic compound salt
WO2017055316A1 (en) 2015-10-01 2017-04-06 Bayer Pharma Aktiengesellschaft Amido-substituted azole compounds
WO2017055313A1 (en) 2015-10-01 2017-04-06 Bayer Pharma Aktiengesellschaft Amido-substituted azole compounds
AR108838A1 (es) 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
WO2018078005A1 (en) 2016-10-29 2018-05-03 Bayer Pharma Aktiengesellschaft Amido-substituted azaspiro derivatives as tankyrase inhibitors
WO2018078009A1 (en) 2016-10-29 2018-05-03 Bayer Pharma Aktiengesellschaft Amido-substituted cyclohexane derivatives
WO2018087126A1 (en) 2016-11-09 2018-05-17 Bayer Pharma Aktiengesellschaft Amido-substituted cyclohexane derivatives as inhibitors of tankyrase
CN107721984A (zh) * 2017-11-07 2018-02-23 大连理工大学 一种新型5‑酰胺基‑1,4,5‑三取代的1,2,3‑三氮唑的制备方法
CN107827829A (zh) * 2017-11-07 2018-03-23 大连理工大学 5‑酰胺基‑1,4,5‑三取代的1,2,3‑三氮唑在水相及生物介质中的制备方法
ES2925626T3 (es) 2017-12-19 2022-10-19 Bristol Myers Squibb Co Acidos isoxazol-O-carbamoilciclohexílicos como antagonistas de LPA
WO2019126089A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid pyrazole azines as lpa antagonists
CN112041304B (zh) 2017-12-19 2025-03-07 百时美施贵宝公司 作为lpa拮抗剂的异噁唑n-连接的氨基甲酰基环己基酸
BR112020011965A2 (pt) 2017-12-19 2020-11-17 Bristol-Myers Squibb Company triazol azinas de ácido ciclo-hexílico como antagonistas de lpa
JP7280881B2 (ja) 2017-12-19 2023-05-24 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのシクロヘキシル酸トリアゾールアゾール
KR102726939B1 (ko) 2017-12-19 2024-11-05 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 시클로헥실 산 피라졸 아졸
EP3728209A1 (en) 2017-12-19 2020-10-28 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azines as lpa antagonists
KR102702231B1 (ko) 2017-12-19 2024-09-02 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 피라졸 o-연결된 카르바모일 시클로헥실 산
JP7301839B2 (ja) 2017-12-19 2023-07-03 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのピラゾールｎ－連結のカルバモイルシクロヘキシル酸
JP7256807B2 (ja) * 2017-12-19 2023-04-12 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのシクロヘキシル酸イソキサゾールアゾール
WO2020060915A1 (en) 2018-09-18 2020-03-26 Bristol-Myers Squibb Company Cyclopentyl acids as lpa antagonists
KR102788997B1 (ko) 2018-09-18 2025-03-28 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 옥사비시클로 산
CN111434653A (zh) * 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 三氮唑类化合物及其制备方法与用途
AU2020384883B2 (en) 2019-11-15 2023-11-16 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof
KR20230019880A (ko) 2020-06-03 2023-02-09 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
TWI843503B (zh) 2020-06-03 2024-05-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
US11980609B2 (en) 2021-05-11 2024-05-14 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
CN115745848A (zh) * 2022-12-07 2023-03-07 上海优合生物科技有限公司 一种氨基胍的加工合成工艺

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011159550A2 (en) * 2010-06-14 2011-12-22 Amidra Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonist and uses thereof
WO2011159633A1 (en) * 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Inhalable formulations of lysophosphatdic acid receptor antagonists
PE20140879A1 (es) * 2010-12-07 2014-08-06 Amira Pharmaceuticals Inc Antagonistas del receptor de acido lisofosfatidico para el tratamiento de fibrosis
WO2012138648A1 (en) * 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
CA2844982A1 (en) * 2011-08-15 2013-02-21 Intermune, Inc. Lysophosphatidic acid receptor antagonists
PE20142448A1 (es) * 2012-06-20 2015-01-28 Hoffmann La Roche Compuestos de n-alquiltriazol como antagonistas de lpar

Also Published As

Publication number Publication date
CO7131357A2 (es) 2014-12-01
KR20150011389A (ko) 2015-01-30
PH12014502363A1 (en) 2015-01-12
CA2869564A1 (en) 2013-12-27
WO2013189865A1 (en) 2013-12-27
US20150133512A1 (en) 2015-05-14
MA37762B1 (fr) 2018-04-30
MA37762A1 (fr) 2017-07-31
AU2013279513A1 (en) 2014-10-16
IN2014DN09352A (OSRAM) 2015-07-17
CL2014003241A1 (es) 2015-03-20
MX2014014711A (es) 2015-03-04
UA110310C2 (uk) 2015-12-10
EP2864301A1 (en) 2015-04-29
ZA201408167B (en) 2015-12-23
IL236087A0 (en) 2015-02-01
JP2015520203A (ja) 2015-07-16
CN104395299A (zh) 2015-03-04
SG11201407228PA (en) 2014-12-30
PE20142305A1 (es) 2015-01-16
EA201492281A1 (ru) 2015-04-30
BR112014030674A2 (pt) 2017-06-27

Similar Documents

Publication Publication Date Title
HK1206339A1 (en) N-aryltriazole compounds as lpar antagonists
TWI635083B (zh) １，４－雙取代嗒類似物及運動神經元存活（ｓｍｎ）缺乏相關病況之治療方式
TW419471B (en) Morpholine derivatives useful as tachykinin receptor antagonists, preparation thereof and pharmaceutical composition containing same
US9321738B2 (en) N-alkyltriazole compounds as LPAR antagonists
TWI606039B (zh) Ａｐｊ受體之三唑激動劑
EP1685113B1 (en) Substituted pyrazoles as ppar agonists
CN104395309B (zh) 环状桥头醚dgat1抑制剂
JP2016519674A (ja) 過剰増殖障害を治療または予防するための３−アセチルアミノ−１−（フェニル−ヘテロアリール−アミノカルボニルまたはフェニル−ヘテロアリール−カルボニルアミノ）ベンゼン誘導体
AU2009240856A1 (en) Substituted pyrazoles, compositions containing such compounds and methods of use
CN104411690A (zh) 作为lpar拮抗剂的取代的吡唑化合物
WO2007129745A1 (ja) ヘテロアリールアミド低級カルボン酸誘導体
TW201443046A (zh) 噻二唑類似物及治療ｓｍｎ缺乏相關症狀之方法
TWI592407B (zh) 飢餓素ｏ－醯基轉移酶抑制劑
CN113727973A (zh) 可用作类法尼醇x受体调节剂的取代酰胺化合物
US9493430B2 (en) Biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds as CETP inhibitors
CN106604918B (zh) 多环hERG激活剂
TW201625613A (zh) 作為生長激素釋放肽受體激動劑之四氫吡唑並吡啶衍生物
WO2017008681A1 (zh) 酰胺类衍生物、其制备方法及其在医药上的用途
TW201617314A (zh) 羧酸衍生物
UA48157C2 (uk) Мономери 4,4-(двозаміщених)циклогексан-1-олів, фармацевтична композиція та спосіб лікування астми
CN117043157A (zh) Erap抑制剂